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Abstract 
Peptide therapeutics are new modalities offering several challenges to drug discovery. They are generally 
less stable and permeable in vivo. The characterization of their lipophilicity cannot be carried out using the 
traditional in silico or wet octanol/water partition coefficients. The prediction of their in vivo distribution 
and permeability is also challenging. In this paper, it is demonstrated that the biomimetic properties such 
as lipophilicity, protein and phospholipid binding can be easily assessed by HPLC using chemically bonded 
protein and immobilized artificial membrane (IAM) stationary phases. The obtained properties for a set of 
potential therapeutic peptides with 3 to 33 amino acids have been analysed and it was found that similar 
characteristics of the properties could be observed as for small molecule drugs. The albumin binding 
showed correlation with their measured lipophilicity on the C-18 stationary phase with acidic peptides 
showing stronger than expected albumin binding. The (IAM) chromatography revealed peptide membrane 
affinity, which was stronger for positively charged peptides (containing arginine) and showed correlation to 
the alpha-1-acid glycoprotein (AGP) binding, which was also stronger for positively charged compounds. 
The in vivo volume of distribution and drug efficiency of the peptides have been estimated using the models 
developed for small molecules. One of the candidate linear peptides has been assessed in various cellular 
and in vivo assays and the results have confirmed the estimated cell partition and brain to plasma ratio. It 
can be demonstrated, that up to 21 amino acids, the peaks of the peptides obtained on the protein phase 
were symmetrical and narrow. The interaction of larger peptides with the protein stationary phases 
resulted in wide peaks showing multiple equilibrium processes with slow kinetics during chromatography. 
The larger peptides showed narrow and symmetrical peaks on the IAM column enabling the quantification 
of peptide - cell membrane interactions. 
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Introduction 
Pharmaceutical and drug discovery companies are searching for new modalities outside the traditional 
small molecular drug space. Peptides, defined as having less than 50 amino acids, have been long 
recognized as potential therapeutics [1]. More than 140 peptides are now in clinical trials and more than 
60 peptide drugs have been approved by FDA [2]. The therapeutic area ranges from antimicrobial to 
anticancer, but it is continuously expanding to new areas such as irritable bowel syndrome (linaclotide), 
Cushing’s syndrome (pasireotide), myeloma (carfilzomib) and a few new peptides in Phase III clinical trials 
for osteoporosis and type II diabetes. It is worth mentioning that 6 peptides therapeutics out of 14 which 
are in Phase III clinical trials [1] are targeting central nervous system (CNS). Peptide therapeutics are able to 
inhibit protein-protein interactions (PPI) and are opening up numerous PPI targets for peptides and 
macrocyclic large molecules that are outside the traditional drug property space as defined by the Lipinski 
rule of five [3]. In general, peptides are selective and efficacious signalling molecules such as hormones, 
neurotransmitters, growth factors and ion channel ligands.  
However, there are several issues with peptide therapeutics that have to be resolved. In spite of usually 
being water soluble, their oral absorption is compromised because of peptide hydrolysis occurring in the 
gastrointestinal tract. Proteolytic enzymes can decompose peptides quickly resulting in short plasma half-
life even when the peptides are administered intravenously [4]. Approaches to extend the plasma half-life 
include substitution of cleavage sites by other amino acids, or to change the folding through enhancement 
of the secondary structure of the peptide. It is common to use lactam bridges, cyclisation and acylation. 
Another approach is to increase the serum albumin binding of peptide therapeutics to potentially increase 
the plasma half-life [4]. Therefore, measurements of albumin binding of potential peptide therapeutics are 
very important. 
It is possible that pharmacologically active peptide therapeutics do not necessarily possess long plasma 
half-lives. For example, studies on SGX93 (Soligenix Inc) [5], a short peptide drug candidate that exhibited 
potential in oral mucositis in clinical trials showed a rapid degradation in plasma.  
Due to their polar nature, peptides often have limited cell permeability. Cyclisation, reduction of the H-
bond donor groups and other methods have been tried to identify cell-permeable peptides (CPP) [6-7]. 
There are three possible mechanisms by which peptides can enter into the cell: 1. the inverted micelle 
model; 2. direct penetration and 3. endocytic uptake [8]. When the target is intracellular it is important to 
design cell penetrating peptide therapeutics [9-10]. Various mechanisms on how peptides can enter into 
the cells have been reviewed by Madani et al. [11]. All of the aforementioned mechanisms require the 
peptide to have good affinity to the negatively charged membrane surface. Thus including arginine in the 
sequence could offer the potential to increases the cell permeability of the peptides [12]. Chromatography 
using immobilized artificial membrane (IAM) as a stationary phase [13-14] is a promising tool to measure 
the affinity of the peptide to the phospholipid membrane and relate it to cell permeability.  
Another aspect of the rational design of peptide therapeutics is to improve their physicochemical 
properties, such as solubility and stability and to avoid aggregation. The stability of peptides can be 
improved by stabilizing α-helixes, salt bridges or lactam bridges. Therefore, several efforts have been 
published [6,15–19], for the synthesis of rigid or flexible cyclic peptides in relation to their cell 
permeability. Due to the low oral bioavailability of peptides, various formulation strategies have been 
developed such as liquid formulations. The search for a non-conventional administration route such as 
inhaled, topical or intravenous is a potential option to improve bioavailability. 
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Therefore, any predictive tool that can be used to estimate the in vivo distribution of potential peptide 
therapeutics would be very valuable.  
Lipophilicity of molecules, expressed as an octanol/water partition coefficient (log D), has been used 
traditionally to model biological distribution processes [20]. It was found that the traditional octanol/water 
partition coefficient measurements were not suitable for the lipophilicity determination of peptides as 
peptides are charged and very polar and do not partition into octanol at all [21]. Moreover it is likely 
peptides could be concentrated on the interface between the octanol and the water. For instance, surface 
active peptides may help to form foams and emulsions that make the log D determination very difficult. 
 There is a study that describes a possible calculation method using 3D descriptors for the lipophilicity of 
the peptides in the octanol/water system [22]. In silico calculation software for log D provides very low 
calculated lipophilicities (below -5 and -10) in most cases. For example, in this study the calculated log D 
values using ACDLabs (Advanced Chemical Development Inc. Toronto, Canada) software for LP5 was -9.27 
and for LP7 it was -9.84. On the other hand, these two compounds showed interactions with the IAM 
stationary phase and also had retention on the C-18 stationary phase.  
Ermondi et al. [23] demonstrated that reversed phase chromatography could be used to assess and 
compare the lipophilicity of peptides. Others have also reported [24-25] that the lipophilicity of peptides is 
an important physicochemical property and that reversed phase chromatography can provide a tool to 
assess lipophilicity via retention time measurements. Biswas et al. [25] applied reversed-phase 
chromatography for lipophilicity assessment of amino acids and established an additivity rule of 
lipophilicity of peptides up to 15 amino acids. However, the additivity rule appeared to break down in 
larger peptides due to the secondary structure formation. In silico predictions of reversed phase retention 
may provide the possibility to assess the lipophilicity of peptides based on the retention coefficients for 
amino acids [26-28]. Gussakovsky et al. [29] analysed over 29 thousand tryptic peptides on the IAM.PC.DD2 
stationary phase and compared the retention contribution of the amino acids with those from the C-18 
columns. They found that amino acids containing positive charges such as arginine and lysine retain 
stronger on the IAM phase than on the C18 phase. They also determined that the amino acid contributions 
depended on the location of the amino acid in the sequence. 
In this paper, we have investigated the retention behaviour of 20 potential peptide therapeutics, (one 
of them has been tested in vivo) including linear and bicyclic peptides on reversed-phase and biomimetic 
HPLC stationary phases such as human serum albumin (HSA), alpha-1-acid-glycoprotein (AGP) and IAM 
phases [14,30,32]. The measured properties have been analysed in comparison to marketed drugs’ 
properties. The models developed for small molecules have been applied to the peptides to predict in vivo 
distribution and cell penetration. 
Experimental  
All chromatographic measurements were carried out on an Agilent 1100 series HPLC equipped with a 
UV-Diode Array Detector. 
Lipophilicity measurements using C-18 stationary phase with acidic, neutral and basic pHs 
The reversed phase fast gradient retention times have been measured using a Gemini NT C-18 column 
with the dimensions of 50 x 3 mm, particle size 5 µM with a 110 Å pore size (Phenomenex UK). The starting 
mobile phase was 0.01 M formic acid at pH 2.6 for low pH lipophilicity, 50 mM ammonium acetate buffers 
with pH adjusted to 7.4 and 10.5 by concentrated ammonia solution for neutral and basic pH lipophilicity 
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measurements, respectively. All reagents were HPLC grade obtained from Honeywell/Sigma-Aldrich, 
Germany. A 1.00 ml/min flow rate was applied. The acetonitrile gradient was from 0 to 100 % from 0 to 3.5 
min then 100 % acetonitrile was kept until 4.5 min and then returned to 0 % at 4.7 min. The run time was 6 
min. HPLC grade water and acetonitrile were obtained from Rathburn Chemicals Ltd, Walkerburn, UK. The 
gradient retention times were standardized using the Valko test mixture and the chromatographic 
hydrophobicity index (CHI) values as described previously [14,32]. The CHI values were converted to the 
octanol/water log D scale using Equation 1. 
CHI log D = 0.0525 CHI – 1.467 (1) 
In this way, the peptides lipophilicity can be compared to their octanol/water lipophilicity. 
Measurements of membrane binding using immobilized artificial membrane (IAM) chromatography 
For the measurements of the peptides interactions with phospholipids, the gradient retention times of 
the peptides have been measured using IAM.PC.DD2 100 x 4.6 mm column with 10 µM diameter and 300 Å 
pore size particles. The starting mobile phase was 50 mM ammonium acetate with the pH adjusted to 7.4. 
The acetonitrile gradient was applied from 0 to 90 % from 0 to 4.75 min and kept at 90 % until 5.25 min. 
From 5.25 to 5.5 min the acetonitrile concentration was dropped to 0. The mobile phase flow rate was 1.5 
ml/min and the run time was 6 min. The retention times were standardized using the IAM calibration 
mixture as described previously [33]. The natural state of the phosphatidyl choline headgroup on the IAM 
stationary phase was tested using the six system suitability test compounds listed in Table 1. The CHI IAM 
values were converted to the octanol/water scale using Equation 2 [33]. 
log KIAM = 0.29*exp(0.046 CHI IAM+0.42) + 0.70 (2) 
The log KIAM values express the membrane partition comparable to the octanol/water lipophilicity. 
Table 1. The IAM system suitability test compounds and their expected CHI IAM values [14]. 
Compound Acid/base Typical retention 
time (min) 
CHI IAM 
Carbamazepine Neutral 2.98 22.3 
Colchicin neutral 3.31 28.0 
Warfarin Acidic 2.62 16.4 
Indomethacin Acidic 3.15 25.3 
Nicardipine Basic 4.38 46.1 
Propranolol Basic 4.72 51.9 
Protein binding measurements using biomimetic protein stationary phases 
The peptides interactions with HSA and AGP have been measured using commercially available 
chemically bonded HSA (Chiralpak-HSA) and AGP (Chiralpak-AGP) HPLC columns with the dimensions of  
50 x 3 mm with 5 µM particle size obtained from HiChrom Ltd, Reading, UK. The mobile phase was 50 mM 
ammonium acetate with the pH adjusted to 7.4. An iso-propanol gradient (HPLC grade, Rathburn 
Chemicals, Walkerburn, Uk) was used from 0 to 35 % from 0 to 3.5 min with a flow rate of 1.5 ml/min. The 
35 % iso-propanol mobile phase was run till 4.5 min and then back to 0 % within 0.2 min. The run time was 
6 min to allow re-equilibrate of the protein phase with the buffer. The retention times were standardized 
using the calibration set of compounds as described previously. Using the slope and intercept values from 
the calibration line the logarithmic retention times were converted to log k values that can be converted to 
% binding values (% HSA and % AGP) using Equation 3 [34]. 













 Compounds studied 
The linear peptides were obtained from GENERVON Biopharmaceuticals LLC (California, USA). These 
peptides were discovered as endogenous motor neuron trophic peptides that have a great potential to 
cure amyotrophic lateral sclerosis (ALS). The peptide with 6 amino acids (GM6) has already been tested in 
animal models of ALS and in Phase II human clinical trials. The analogues are marked as linear peptides (LP) 
with a serial number. 
The bicyclic peptides were obtained from BiCycle TX, Cambridge, UK and are marked as BCP with a 
serial number. These are in the early stages of the drug discovery process. 
Data analysis 
The calculation of the biomimetic binding properties from the measured retention time values and 
estimating the in vivo distribution characteristics and cellular concentration [35] are based on the 
published models [36] and have been carried out using the Bio-Mimetic Chromatography Ltd propriety 
excel macros. The statistical analysis was carried out using JMP 13 (SAS Institute, USA) and the 
visualizations have been made by Stardrop software (Optibrium Ltd. Cambridge, UK). 
Results and Discussion 
The chromatographic peaks were symmetrical and narrow on the C18 and IAM stationary phases. A few 
examples are shown in Figure 1. However, larger peptides (containing more than 10 amino acids) showed 
wide peaks on the HSA column with a narrow peak at the dead time showing a size exclusion effect (Figure 
2). Size exclusion occurs when large molecules cannot get into the pores of the stationary phases and elute 
with short retention times. It is worth mentioning that the Gemini NT C-18 column particle pore size is 110 
Å and the IAM PC.DD2 column pore size is 300 Å and that would not produce a size exclusion effect for 
peptides below 3000 Da molecular weight. The good peak shape also suggests single interaction points 
between the peptide and the stationary phase on the C-18 and on the IAM stationary phases. 
The broad peak observed for LP10 indicates multiple binding interactions with a slow kinetics between 
the peptide and the protein. The bicyclic peptides also showed broad peaks both for compounds with 
shorter and longer retention times. The peak shape of the linear peptides was narrow and symmetrical up 
to 21 amino acids.  
Table 2 shows the measured data for 10 linear and 10 bicyclic peptides. The lipophilicity difference at 
acidic, neutral and basic pHs reveal the overall charges on the molecules at physiological pHs and whether 
the peptides are more positively or negatively charged. 
It has been found that the pH dependence of the gradient retention times shows a similar profile to the 
pH dependence of the octanol/water distribution coefficients (log D) [37]. If the lipophilicity increased at a 
basic pH relative to the neutral pH lipophilicity, it would suggest that the peptide has more positive than 
negative charge. If the lipophilicity increases at an acidic pH, the peptide has more negative charge. It can 
be seen that the linear peptides are positively charged at physiological pH, while BCP1, BCP2 and BCP10 
have more negative charge at physiological pHs. When plotting the CHI log D at pH 7.4 as a function of the 
molecular weight, we can see some trends for the linear peptides as shown in Figure 3.  
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Table 2. The measured protein binding (%HSA, log k HSA, %AGP, log k AGP), phospholipid binding (CHI IAM, log 
K IAM) and lipophilicity at three pHs (CHI log D 2.6, CHI log D 7.4, CHI log D 10.5) and phospholipid binding of 
the investigated linear (LP) and bicyclic peptides (BCP). The data of the known macrocyclic drug, cyclosporine is 















CHI log D 
2.6 
CHI log D 
7.4 
CHI log D 
10.5 
LP1 7.85 -1.07 3.70 -1.42 5.47 1.27 -1.94 -0.54 -0.50 
LP2 13.58 -0.81 6.85 -1.14 15.32 1.59 -0.75 -0.26 -0.23 
LP3 13.15 -0.82 6.82 -1.14 17.46 1.69 -0.71 -0.14 -0.11 
LP4 24.87 -0.49 61.24 0.19 43.04 3.90 -3.39 -0.14 0.22 
LP5 20.73 -0.59 37.97 -0.22 42.25 3.78 -3.37 -0.17 0.19 
LP6 77.54 0.52 49.58 -0.02 25.82 2.15 0.87 1.01 1.05 
LP7 52.66 0.04 69.83 0.35 43.29 3.93 -0.15 0.77 1.07 
LP8 95.75 1.26 74.92 0.46 37.47 3.17 0.18 0.83 0.82 
LP9 98.97 1.69 89.84 0.91 43.80 4.01 1.18 1.59 0.61 
LP10 99.07 1.71 87.83 0.82 37.66 3.20 1.17 1.60 0.61 
BCP1 71.25 0.38 63.54 0.23 16.51 1.64 0.98 0.59 0.28 
BCP2 88.58 0.85 1.31 -1.88 17.84 1.70 1.11 0.75 0.36 
BCP3 19.03 -0.63 1.30 -1.89 16.10 1.63 0.24 0.54 0.25 
BCP4 18.24 -0.66 35.68 -0.26 32.48 2.67 0.02 0.89 0.38 
BCP5 92.92 1.06 73.34 0.42 39.98 3.48 0.89 1.79 1.54 
BCP6 26.00 -0.46 2.69 -1.56 21.77 1.90 0.75 0.84 0.56 
BCP7 9.24 -1.00 1.58 -1.80 18.08 1.71 0.57 0.65 0.36 
BCP8 94.41 1.16 83.76 0.69 44.90 4.18 1.02 1.79 1.70 
BCP9 82.29 0.64 32.81 -0.32 25.91 2.15 1.00 1.20 0.93 
BCP10 96.28 1.31 49.46 -0.02 21.50 1.89 2.27 1.23 0.92 
CP 91.00 0.97 60.9 0.18 51.33 5.38  5.31  
 
Figure 1. Chromatograms of LP2 and LP8 obtained on Gemini NX C-18 and IAM.PC.DD2 columns at pH 7.4.  
a) LP2 C-18 column, b) LP8 on C-18 column, c) LP2 on IAM.PC.DD2 column, d) LP8 on IAM.PC.DD2 column 
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Figure 2. The chromatogram obtained on CHIRALPAK-HSA column for LP4 (a) and LP10 (b). Chromatographic 
conditions as described in the experimental section. 
 
Figure 3. The CHI log D7.4 values of the investigated peptides as a function of their molecular weight. 
 
Figure 4. The CHI IAM values of the investigated peptides as a function of molecular weight. 
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Figure 5. The human serum albumin binding (log kHSA) of the investigated peptides as a function of molecular 
weight. 
From LP1 to LP10 the lipophilicity increases with size, while LP6 is slightly more lipophilic. With the 
linear peptides (LP8 and LP10) the lipophilicity increased but not proportionally with their larger molecular 
weight. This is in agreement with the finding that peptides with more than 16 amino acids start to fold and 
have secondary structure that may hinder the effect of certain amino acids on their lipophilicity [25]. 
Similar trends have been observed on the IAM.PC.DD2 stationary phase. The interactions with the 
phospholipid increased with the increasing number of amino acids as shown in Figure 4. The trend breaks 
for larger amino acids. Interestingly, the candidate peptide drug LP4 has stronger interactions with the 
phospholipids than the trend would show with the molecular weight due to its positive charge having two 
arginine in its sequence.  
Figure 5 shows a similar plot for the human serum albumin binding in the function of molecular weight. 
For the linear peptides, as the amino acid number increase, the albumin binding increases up to LP8. 
Although the albumin binding is stronger for LP8 and LP10, it does not increase proportionally with the 
molecular weight. Some of the bicyclic peptides showed much weaker albumin binding, probably because 
the cyclization hindered several amino acids’ interactions with the protein. Almost all of the bicyclic 
peptides showed wide peaks on the protein phases indicating multiple equilibria and sluggish kinetics.  
Based on the measured biomimetic properties we have estimated the in vivo distribution behaviour of 
the investigated compounds. The model equations with the source references are listed in Table 3. 
Table 4 contains the calculated total plasma protein binding (log k PPB), brain to plasma total 
concentration ratio (log k BB, Brain to plasma ratio), volume of distribution (log Vdss and Vdss L/kg), 
unbound volume of distribution (log Vdu, Vdu), drug efficiency (DEmax%) and estimated cell partition 
(Kpcell) data. The brain to plasma total concentration ratio has been calculated using the plasma protein 
binding (%PPB) and brain tissue binding (%BTB) models shown in Table 3 and described in [35]. From the 
%PPB and %BTB we can calculate the unbound fraction of the peptides (fu) in plasma and brain tissue using 
the equations listed in Table 3. According to the free drug hypothesis, the unbound concentration in 
plasma (cu,plasma) and brain (cu, brain ) should be equal. The unbound concentrations can be expressed as fu 
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times ctotal which leads to equation 4. 
Table 3. The model equations used to derive estimated in vivo distribution (log Vdss, log Vdu), 
drug efficiency (DEmax), brain tissue binding (log kBTB), fraction unbound in brain and plasma 
(fu BTB and fu PPB), brain to plasma ratio (kbb) and cell partition log Kpcell). 
log KIAM [33] = 0.29*e
(0.026CHI(IAM)+0.42
) + 0.7 
Log kIAM [33] =0.046*CHI(IAM) + 0.42 
log KHSA [33] = e
log k(HSA) 
 
log kHSA [34] = log (%HSAbound/(101- %HSA bound))  
Estimated log Vdss [33] = 0.44*log KIAM -0.22*log KHSA - 0.62  
Estimated log Vdu [38] = 0.23*log KHSA +0.43*log KIAM - 0.72  
DEmax [39] = 100/Vdu  
log kBTB [36] =1.29*log kIAM+1.03*log kHSA - 2.37 
log kPPB [36] =0.98∗log 𝑘𝐻𝑆𝐴+0.19∗log 𝑘𝐴𝐺𝑃+0.031∗CHI log D7.4−0.20  
%BTB [36] =100*10^log kBTB/(1+10^log kBTB) 
%PPB [36] =100*10^log kPPB/(1+10^log kPPB) 
fu BTB and PPB [36] =(100-%BTB)/100 and (100-%PPB)/100 
Kbb [36] = fuPPB/fuBTB 
log Kpcell [35] =1.1*log kIAM - 1.9 
 
fu, plasma x cT, plasma = fu, brain x cT, brain       (4) 
Expressing the ratio of the total concentrations from equation 4, the equation for kbb can be obtained 
and is listed in Table 3. Drugs that are able to go to the central nervous system (CNS) have significantly 
higher kbb values than drugs that do not partition into the CNS. When kbb is larger than 1 it means that the 
total concentration of the compound in the brain is higher than in the plasma. Therefore it is very likely 
that the compounds partition into the brain tissue (unless active transporters efflux the compound back to 
the plasma). 
As the peptides easily decompose in plasma or blood under in vitro experimental conditions, it is very 
useful to estimate the peptides in vivo distribution behaviour considering them as intact molecules. The 
data in Table 4 reveals that there is a wide range of estimated total plasma protein binding in spite of the 
polar character of the peptides. The brain to plasma distribution ratio is generally low but some of the 
derivatives especially those that have positively charged amino acids, particularly with an arginine in the 
sequence, bind more strongly to phospholipids than to albumins thus increasing the expected brain to 
plasma total concentration ratio. The linear peptides are designed as candidate therapeutics for 
amyotrophic lateral sclerosis (ALS). Therefore brain penetration and cellular penetration are desired for 
these peptides. We can see from the measured data that LP4 (GM6 patented by Genervon) is predicted to 
have a good brain to plasma ratio. The volume of distribution is also quite large which means that it 
partitions into tissues extensively. Peptides that are more lipophilic at high pH (CHI log D at pH 10.5 is 
greater than CHI log D at pH 7.4) are predicted to have good cell penetration and the brain to plasma ratio 
is predicted to be greater than 1. This is because the phospholipid binding of positively charged peptides is 
stronger than that of the neutral molecules. 
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log k BB Brain to 
plasma 
log Vd Vd L/kg log Vdu Vdu % 
DEmax 
Kpcell 
LP1 6.85 -1.14 -0.03 0.93 -0.18 0.66 -0.10 0.80 124.83 0.07 
LP2 13.36 -0.82 -0.05 0.88 -0.06 0.88 0.07 1.17 85.62 0.22 
LP3 13.03 -0.83 -0.05 0.89 -0.01 0.97 0.11 1.27 78.44 0.28 
LP4 36.55 -0.25 0.23 1.70 0.92 8.29 1.10 12.49 8.00 5.49 
LP5 27.63 -0.42 0.20 1.58 0.88 7.62 1.03 10.82 9.25 5.01 
LP6 85.20 0.73 -0.39 0.40 -0.08 0.82 0.59 3.89 25.70 0.74 
LP7 68.47 0.32 0.34 2.21 0.84 6.96 1.21 16.23 6.16 5.66 
LP8 98.17 1.54 -0.04 0.92 -0.04 0.91 1.46 28.62 3.49 2.87 
LP9 99.99 2.00 -1.49 0.03 -0.08 0.82 2.25 176.76 0.57 6.00 
LP10 99.99 2.00 -1.83 0.01 -0.47 0.34 1.92 84.13 1.19 2.93 
BCP1 81.77 0.63 -0.25 0.25 -0.26 0.55 0.32 2.10 47.56 0.25 
BCP2 84.04 0.70 0.19 0.36 -0.43 0.37 0.55 3.56 28.06 0.29 
BCP3 14.84 -0.76 -0.01 0.88 -0.06 0.87 0.10 1.26 79.24 0.24 
BCP4 25.70 -0.47 -0.03 0.94 0.40 2.51 0.55 3.51 28.47 1.60 
BCP5 96.85 1.37 0.52 1.40 0.23 1.72 1.44 27.51 3.64 3.85 
BCP6 23.29 -0.52 0.00 0.84 0.04 1.09 0.24 1.75 57.17 0.46 
BCP7 7.46 -1.10 -0.02 0.94 0.01 1.03 0.10 1.26 79.11 0.30 
BCP8 97.98 1.51 0.63 2.17 0.48 3.03 1.81 64.42 1.55 6.82 
BCP9 87.21 0.80 0.11 0.43 -0.13 0.74 0.64 4.40 22.72 0.75 
BCP10 97.97 1.51 -0.38 0.15 -0.64 0.23 0.94 8.77 11.40 0.45 
CP 100 2.00 0.78 5.63 1.13 13.39 2.20 158 0.68 14.43 
It is well known that cell penetration of peptides is usually impaired, as they are very hydrophilic and 
cannot go through the cell membrane with the same mechanism as small molecules [8]. 
However, endocytosis or micelle formation with phospholipids are possible cell penetration 
mechanisms which require strong interactions between the peptides and the phospholipid membrane. 
The model for cell partition has been investigated using small molecule partition into HELA cells [35] 
and it was found that the IAM partition correlated better with intracellular concentration than other 
lipophilicity values. Therefore, the cell partition (Kp cell) has been estimated using the correlation with the 
IAM retention. Although the distribution models have been developed using the properties of small 
molecule marketed drugs based on their clinical data, it was supposed that the same models could be 
applied to peptides. Diaz-Eufracio et al [40] have compared the physicochemical property space of 
marketed peptide therapeutics with other marketed drugs and they found that they occupy similar 
property space. This study suggests that physicochemical properties of the peptides are not significantly 
different from small molecule marketed drugs and the drug-like properties can be described by the same 
physicochemical properties. They used calculated physicochemical properties. In this study, the measured 
physicochemical and biomimetic properties are compared with marketed drugs [36] and macrolides [41]. 
The marketed drugs were divided into inhaled and CNS group. A cyclic peptide natural product drug 
Cyclosporine (marked as CP) was also included in the analysis. Figure 6a shows the lipophilicity distribution 
and Figure 6b shows the IAM binding distribution of the peptides and the marketed drugs. It can be seen 
that the peptides are less lipophilic but their membrane partition (IAM binding) is within the range of other 
drug molecules. 





Figure 6. The lipophilicity (CHI log D7.4) (a) and membrane partition (CHI IAM) (b), of the peptides in 
comparison to macrocycle (MC), small molecule drugs (DRUG), inhaled drugs and drugs that can go to the 
central nervous system (CNS). CP stands for the natural cyclic peptide drug Cyclosporin. 
The estimated brain to blood ratio (log k BB) and cell partition (log Kpcell) have been also compared 
based on the measured HPLC based biomimetic properties for the peptides, for the known drugs and for 
the macrolides as shown in Figure 7.  
a) b) 
  
Figure 7. Distribution of the estimated brain to blood ratio (log k BB) (a) and cell partition (Kpcell) (b), for the 
peptides in comparison to macrocycle (MC), small molecule drugs (DRUG), inhaled drugs and drugs that can 
go to the central nervous system (CNS). CP stands for the natural cyclic peptide drug Cyclosporin. (The 
macrocycles (MC) did not have all the data for estimating the log k BB therefore they are not shown in (a) 
The interrelationship between the measured lipophilicity and biomimetic properties of the peptides 
have been investigated and a comparison made to the marketed drugs. In every respect, very similar 
relationships were observed. Figure 8 shows a good trend between the AGP and IAM binding of the 
compounds, as both bindings are influenced by the presence of the positive charge and general lipophilicity 
of the compounds. Both the linear and the cyclic peptides follow the same trend as the marketed drugs 
and macrolides. 
One of the investigated compounds, Genervon’s GM6 has been evaluated in vivo in a mouse model and 
also in humans. It has shown an effect in the SOD1 mouse model for ALS and in ALS patients [42] . As 
predicted, the peptide has been detected in the cells, especially in the motoneuron cells and was strongly 
associated with the cell membrane as confirmed using immune imaging technology. GM6 (LP4) has also 
been detected in the cerebrospinal fluid in mice after 4 hours. 
These preliminary results encourage further studies of new modalities, such as peptides, cyclic peptides 
and macrocycles using biomimetic chromatographic methods and models. 
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Figure 8. The trend between the alpha-1-acid glycoprotein binding (log k AGP) and phospholipid binding (log k 
IAM) for peptides, marketed drugs and macrolides. (Colour code is the same as in Figure 6 and 7. 
Conclusions 
The HPLC based physicochemical and biomimetic property measurements have been carried out on 
linear and bicyclic peptides. The measured properties, such as lipophilicity expressed as CHI log D, 
phospholipid binding expressed as CHI IAM (log k IAM) and protein binding (%HSA and %AGP) of selected 
linear and bicyclic peptides have been compared to the similar measured properties of marketed drugs. 
The lipophilicity, phospholipid binding and protein binding have been compared to the molecular weight of 
the peptides. It was found that larger molecular weight peptides had greater lipophilicity, phospholipid and 
protein binding; however, the trend was broken for bicyclic peptides and linear peptides above 16 amino 
acids. It suggests that the effect of the amino acids on the interactions with lipids and proteins are shielded 
for larger or cyclic peptides. The in vivo distribution models developed for small molecules have been 
applied for the first time to peptides. The estimation of good cell and brain penetration for LP4 (GM6), a 
linear peptide with 6 amino acids, has been validated in in vitro assays. Biomimetic HPLC measurements 
can, therefore, contribute to the design of peptide therapeutics with good drug-like properties. 
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